PlexBio Co., Ltd. (TPEX:6572)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
10.10
-0.55 (-5.16%)
May 8, 2026, 1:55 PM CST
Market Cap1.07B +9.4%
Revenue (ttm)127.10M -0.8%
Net Income-62.47M
EPS-0.60
Shares Out103.65M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume195,095
Average Volume1,264,320
Open10.65
Previous Close10.65
Day's Range10.00 - 10.65
52-Week Range5.16 - 15.80
Beta1.29
RSI53.68
Earnings DateMay 11, 2026

About PlexBio

PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for πCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and πCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan. [Read more]

Sector Healthcare
Founded 2009
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6572
Full Company Profile

Financial Performance

In 2025, PlexBio's revenue was 127.10 million, a decrease of -0.76% compared to the previous year's 128.06 million. Losses were -62.47 million, 1.36% more than in 2024.

Financial Statements